A Prospective Multicenter Randomized Double-blind Placebo-controlled Study in Parallel Groups to Evaluate the Efficacy, Safety, and Tolerability of the Drug 4-MUST, Tablets, 128 mg Administered at Various Doses in Patients With Chronic Cholecystitis and Biliary Dyskinesia
Latest Information Update: 24 Jul 2025
At a glance
- Drugs 4 methylumbelliferyl trimebutine sulfate (Primary)
- Indications Biliary dyskinesia; Cholecystitis
- Focus Therapeutic Use
- Sponsors Valenta Pharmaceuticals
Most Recent Events
- 28 Feb 2025 New trial record